This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sigel, M. M. Articles by Ortiz-Muniz, G. Search for Related Content PubMed PubMed Citation Articles by Sigel, M. M. Articles by Ortiz-Muniz, G.

In Vitro Immune Responses to Viral and Tumor Antigens in Murine Breast Cancer¹

Laboratory of Virology, Department of Microbiology, University of Miami School of Medicine, Miami, Florida 33152

Inhibition of migration of peritoneal exudate cells proved to be a useful measurement of cell-mediated immunity which correlated in several respects with blastogenic transformation reactions.

Lectins (phytohemagglutinin and concanavalin A) inhibited the migration of peritoneal exudate cells from normal and tumor-bearing mice, whereas tumor antigen caused inhibition of migration of cells from tumor-bearing animals only. The disparity in immunogenic capacity previously observed with lymphocyte transformation studies was also manifested in migration inhibition, i.e., D1-DMBA-3 tumor being immunogenic and D1-DMBA-2 being nonimmunogenic.

Using the migration inhibition and blastogenic transformation reactions, responses were obtained to mammary tumor virus (MTV) antigen(s) in cells from BALB/cCrgl mice, which are free of MTV. In contrast, cells from MTV-positive BALB/cfC3H mice failed to respond to this antigen(s) in both reactions, suggesting a form of tolerance. However, the reactions became positive after implantation with MTV-containing spontaneous mammary tumors. Two possible explanations of the origin of reactive lymphocytes, horizontal transmission, or activation of a gene coding for an MTV antigen(s), are discussed.

¹ Presented at the symposium "Immunological Control of Virus-associated Tumors in Man: Prospects and Problems," April 7 to 9, 1975, Bethesda, Md. Supported by Contract NO1 CP 43358 from the Virus Cancer Program of the National Cancer Institute, USPHS.

² Presenter.